Phase III study of aldoxorubicin vs investigators' choice as treatment for relapsed/refractory soft tissue sarcomas

被引：36

作者：

Chawla, Sant P.

Ganjoo, Kristen N.

Schuetze, Scott

Papai, Zsuzsanna

Van Tine, Brian Andrew

Choy, Edwin

Liebner, David A.

Agulnik, Mark

Chawla, Shanta

Wieland, Scott

Levitt, Daniel J.

机构：

[1] Sarcoma Oncol Ctr, Santa Monica, CA USA

[2] Stanford Canc Inst, Stanford, CA USA

[3] Univ Michigan, Ann Arbor, MI 48109 USA

[4] Magyar Honvedseg Egeszsegugyi Kozpont, Budapest, Hungary

[5] Washington Univ, St Louis, MO USA

[6] Massachusetts Gen Hosp, Boston, MA 02114 USA

[7] Ohio State Univ, Wexner Med Ctr, Columbus, OH 43210 USA

[8] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA

[9] CytRx Corp, Los Angeles, CA USA

来源：

关键词：

D O I：

10.1200/JCO.2017.35.15_suppl.11000

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

11000

引用

页数：5